The present invention relates to the pharmaceutical field, and disclosed a novel nitrogen heterocyclic derivative, a method for preparing the same, and use as a pharmaceutical, particularly a pharmaceutical for treating, preventing, and treating tissue fibrosis. The present invention also discloses a pharmaceutical composition comprising a pharmaceutically acceptable compound of the present invention and a use for treating a tissue fibrosis disease of a human body or an animal using the composition. In particular, human or animal renal interstitial fibrosis, glomerulosclerosis, liver fibrosis, lung fibrosis, peritoneal fibrosis, myocardial fibrosis, skin fibrosis, postoperative adhesion, benign prostatic hyperplasia, skeletal muscle fibrosis, Applications for the treatment of scleroderma, multiple sclerosis, pancreatic fibrosis, cirrhosis, myoma, neurofibroma, lung interstitial fibrosis, diabetic nephropathy, Alzheimer's disease or vascular fibrosis disease have been disclosed. [Selection] Figure 1本発明は医薬品領域に関し、新規の窒素複素環誘導体、その調製方法並びに医薬品、特に組織線維化疾患を治療及び予防・治療する医薬品としての用途が開示された。本発明は薬学的に許容される本発明の化合物を含む医薬品組成物及びその組成物を使用して人体又は動物の組織線維化疾患を治療する用途も開示された。特に、人体又は動物の腎間質線維化、糸球体硬化、肝線維化、肺線維化、腹膜線維化、心筋線維化、皮膚線維化、術後癒着、良性前立腺過形成、骨格筋線維化、強皮症、多発性硬化症、膵臓線維化、肝硬変、筋肉腫、神経線維腫、肺間質線維化、糖尿病性腎症、アルツハイマー病又は血管線維化疾患の治療への用途が開示された。【選択図】 図１
